Phase III study of S-1 plus intravenous and intraperitoneal paclitaxel versus S-1 plus cisplatin for gastric cancer with peritoneal metastasis.

Trial Profile

Phase III study of S-1 plus intravenous and intraperitoneal paclitaxel versus S-1 plus cisplatin for gastric cancer with peritoneal metastasis.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Cisplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms PHOENIX-GC
  • Most Recent Events

    • 07 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Primary endpoint (Overall survival) has not been met according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results assessing efficacy of intraperitoneal paclitaxel plus S-1/paclitaxel compared to standard chemotherapy presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top